Novacyt S.A.

("Novacyt", the "Company" or the "Group")

Notice of rescheduled AGM

AGM to be held in Paris on Thursday 26 October

Paris, France and Eastleigh, UK - 05 October 2023 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company's Annual General Meeting (AGM), due to take place earlier today, will be rescheduled and held in person in Paris on Thursday 26 October at 1pm BST/2pm CEST.

To function as a procedural meeting, the AGM requires a sufficient number of shareholder votes to constitute a quorum to ensure the AGM is validly held in accordance with French corporate law. This threshold has not been met, therefore, in accordance with Article 19 of Novacyt articles of association, the AGM has been rescheduled.

The rescheduled AGM will be an open meeting exclusively, held in The Hilton Hotel, Paris Charles De Gaulle Airport, and will also be streamed online for those shareholders wishing to join virtually. Online votes will not be open. The agenda will remain the same as in the first convening and the AGM will comprise of both ordinary and extraordinary resolutions.

Shareholders can register to view the AGM via the online meeting platform by visiting https://novacytagm23.eventcaster.co.uk.

Forms of Proxy already completed and submitted and votes cast by electronic means for the first AGM remain valid for all meetings subsequently convened with the same agenda (art. R. 225-77 of the French commercial code). Further information on voting procedures and deadlines will follow in due course.

Contacts

About Novacyt Group

Novacyt is an international diagnostics business delivering a broad portfolio of in vitro and molecular diagnostic tests for a wide range of infectious diseases, enabling faster, more accurate, accessible testing to improve healthcare outcomes. The Company provides customers with a seamless sample-to-result workflow using its integrated and scalable instrumentation/solutions. The Company specialises in the design, manufacture, and supply of real-time PCR kits, reagents and a full range of laboratory and qPCR instrumentation for molecular biology research and clinical use. Novacyt offers one of the world's most varied and comprehensive range of qPCR assays, covering human, veterinary, biodefence, environmental, agriculture and food testing.

The acquisition of Yourgene in September 2023 added a complementary international genomics technology and services business, focussed on delivering accurate molecular diagnostic and screening solutions, across reproductive health and precision medicine. Yourgene's portfolio of in vitro diagnostic products includes non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests and DPYD genotyping assays. Yourgene also works in partnership with global leaders in DNA technology to allow its Ranger® Technology to deliver dynamic target enrichment.

Novacyt is headquartered in Vélizy in France with offices in the UK in Stokesley, Eastleigh and Manchester. The Company also has offices in Taipei (divestment pending), Singapore, the US and Canada and is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

For more information, please refer to the website: www.novacyt.com